or Try an Advanced Search...

    Technical Analysis for MRNS - Marinus Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    F 1.28 9.40% 0.11
    MRNS closed up 9.4 percent on Monday, July 1, 2024, on 1.4 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical MRNS trend table...
    Date Alert Name Type % Chg
    Bullish Engulfing Bullish 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    New 52 Week Closing Low Bearish 9.40%
    Volume Surge Other 9.40%
    Lower Bollinger Band Walk Weakness 9.40%
    New 52 Week Low Weakness 9.40%
    Below Lower BB Weakness 9.40%
    Older End-of-Day Signals for MRNS ...

       Recent Intraday Alerts

    Alert Time
    10 DMA Resistance about 8 hours ago
    Rose Above Previous Day's High about 8 hours ago
    Up 10% about 8 hours ago
    Up 1 ATR about 8 hours ago
    1.5x Volume Pace about 9 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    MRNS Chart by TradingView
    Basic chart:

    Profile

    Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing neuropsychiatric therapeutics. It offers Ganaxolone, a synthetic small molecule, which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures; and is in proof-of-concept Phase II clinical trial as a treatment for behaviors in the orphan indication Fragile X Syndrome in children. The company has a collaboration agreement with NovaMedica, LLC, as well as a license agreement with Purdue Neuroscience Company. Marinus Pharmaceuticals, Inc. was founded in 2003 and is headquartered in New Haven, Connecticut.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Drugs Alcohol Neuroscience Seizure Ketones Sedatives Fragile X Syndrome Pregnanes Neurosteroids

    Is MRNS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 24 PTC Therapeutics (PTCT) Soars 9.7%: Is Further Upside Left in the Stock?
    Jun 18 Marinus Pharmaceuticals reports data from refractory status epilepticus drug trial
    Jun 17 Marinus Pharmaceuticals Epilepsy Treatment Falls Short in Phase 3 Study
    Jun 17 Marinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus
    Jun 13 Avidity (RNA) Up 33% on Rare Muscle Disease Study Results
    Jun 6 Amgen's (AMGN) Uplizna Meets Study Goal for Rare Disease
    May 30 J&J's (JNJ) Oral Pill Improves Depression & Insomnia Symptoms
    May 27 Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data
    May 24 Candel Reports Upbeat Data From Lung Cancer Study
    May 24 Iovance (IOVA) Up 5% on Updated Data From Melanoma Study
    See more MRNS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 11.26
    52 Week Low 1.1
    Average Volume 1,439,061
    200-Day Moving Average 6.55
    50-Day Moving Average 1.41
    20-Day Moving Average 1.41
    10-Day Moving Average 1.32
    Average True Range 0.14
    RSI (14) 35.48
    ADX 29.08
    +DI 12.65
    -DI 22.48
    Chandelier Exit (Long, 3 ATRs) 1.22
    Chandelier Exit (Short, 3 ATRs) 1.52
    Upper Bollinger Bands 1.63
    Lower Bollinger Band 1.19
    Percent B (%b) 0.2
    BandWidth 31.06
    MACD Line -0.16
    MACD Signal Line -0.19
    MACD Histogram 0.0253
    Fundamentals Value
    Market Cap 69.85 Million
    Num Shares 54.6 Million
    EPS -2.78
    Price-to-Earnings (P/E) Ratio -0.46
    Price-to-Sales 17.71
    Price-to-Book 10.10
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.53
    Resistance 3 (R3) 1.52 1.42 1.49
    Resistance 2 (R2) 1.42 1.36 1.43 1.47
    Resistance 1 (R1) 1.35 1.32 1.39 1.36 1.46
    Pivot Point 1.26 1.26 1.27 1.26 1.26
    Support 1 (S1) 1.19 1.19 1.22 1.20 1.10
    Support 2 (S2) 1.09 1.15 1.10 1.09
    Support 3 (S3) 1.02 1.09 1.07
    Support 4 (S4) 1.03